Syndax Pharmaceuticals Statistics Share Statistics Syndax Pharmaceuticals has 86.14M
shares outstanding. The number of shares has increased by 1.12%
in one year.
Shares Outstanding 86.14M Shares Change (YoY) 1.12% Shares Change (QoQ) 0.03% Owned by Institutions (%) 99.99% Shares Floating 72.74M Failed to Deliver (FTD) Shares 53,510 FTD / Avg. Volume 2.38%
Short Selling Information The latest short interest is 23.14M, so 26.86% of the outstanding
shares have been sold short.
Short Interest 23.14M Short % of Shares Out 26.86% Short % of Float 30.34% Short Ratio (days to cover) 12.77
Valuation Ratios The PE ratio is -3.55 and the forward
PE ratio is -8.64.
Syndax Pharmaceuticals's PEG ratio is
-0.14.
PE Ratio -3.55 Forward PE -8.64 PS Ratio 47.8 Forward PS 3.6 PB Ratio 3.93 P/FCF Ratio -4.12 PEG Ratio -0.14
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Syndax Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.82,
with a Debt / Equity ratio of 1.2.
Current Ratio 5.82 Quick Ratio 5.82 Debt / Equity 1.2 Debt / EBITDA -1.1 Debt / FCF -1.26 Interest Coverage -68.91
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $87.7K Profits Per Employee $-1.18M Employee Count 270 Asset Turnover 0.03 Inventory Turnover 2.26
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -16.99% in the
last 52 weeks. The beta is 0.72, so Syndax Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.72 52-Week Price Change -16.99% 50-Day Moving Average 13.92 200-Day Moving Average 12.76 Relative Strength Index (RSI) 56.19 Average Volume (20 Days) 2,243,892
Income Statement In the last 12 months, Syndax Pharmaceuticals had revenue of 23.68M
and earned -318.76M
in profits. Earnings per share was -3.73.
Revenue 23.68M Gross Profit 22.85M Operating Income -339.67M Net Income -318.76M EBITDA -313.82M EBIT -313.83M Earnings Per Share (EPS) -3.73
Full Income Statement Balance Sheet The company has 154.08M in cash and 345.74M in
debt, giving a net cash position of -191.66M.
Cash & Cash Equivalents 154.08M Total Debt 345.74M Net Cash -191.66M Retained Earnings -1.22B Total Assets 596.15M Working Capital 418.69M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -274.9M
and capital expenditures 0, giving a free cash flow of -274.9M.
Operating Cash Flow -274.9M Capital Expenditures n/a Free Cash Flow -274.9M FCF Per Share -3.21
Full Cash Flow Statement Margins Gross margin is 96.51%, with operating and profit margins of -1434.43% and -1346.11%.
Gross Margin 96.51% Operating Margin -1434.43% Pretax Margin -1346.11% Profit Margin -1346.11% EBITDA Margin -1325.26% EBIT Margin -1434.43% FCF Margin -1160.91%
